Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Year: 2019
Type: review
Abstract: Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and although immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognizing potentially life-threatening toxicities and managing them in a timely manner. In this review article, we provide an overview of the clinical features, pathological findings and management principles of common immune-related toxicities, attempting to provide mechanistic insight into an increasingly common complication of cancer therapy.
Source: Immunology
DOI: 10.1111/imm.13141
Authors: Petros Fessas, Lucia A. Possamai, James Clark, Ella Daniels, Cathrin Gudd, Benjamin H. Mullish, James L. Alexander, David J. Pinato
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune checkpoint inhibitors, immunotoxicity, immune-related adverse events, immune-related pneumonitis, immune-related colitis, immune-related endocrinopathy, immune-related encephalitis, immune-related hypophysitis, immune-related hepatitis, immune-related skin toxicity, immune-related nephritis, immune-related myocarditis
Open Access status: bronze
Award: G2346901224
OpenAlex ID: W2981320816
